- Home
- FAAS vs NRSN Comparison
FAAS vs NRSN Comparison
Compare FAAS & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FAAS
- NRSN
- Stock Information
- Founded
- FAAS 2021
- NRSN 2017
- Country
- FAAS Indonesia
- NRSN Israel
- Employees
- FAAS N/A
- NRSN N/A
- Industry
- FAAS
- NRSN Biotechnology: Pharmaceutical Preparations
- Sector
- FAAS
- NRSN Health Care
- Exchange
- FAAS NYSE
- NRSN Nasdaq
- Market Cap
- FAAS 48.2M
- NRSN 50.1M
- IPO Year
- FAAS N/A
- NRSN 2021
- Fundamental
- Price
- FAAS $0.49
- NRSN $2.03
- Analyst Decision
- FAAS
- NRSN Buy
- Analyst Count
- FAAS 0
- NRSN 2
- Target Price
- FAAS N/A
- NRSN $14.00
- AVG Volume (30 Days)
- FAAS 5.8M
- NRSN 236.0K
- Earning Date
- FAAS 01-01-0001
- NRSN 07-29-2025
- Dividend Yield
- FAAS N/A
- NRSN N/A
- EPS Growth
- FAAS N/A
- NRSN N/A
- EPS
- FAAS N/A
- NRSN N/A
- Revenue
- FAAS $57,730,593.00
- NRSN N/A
- Revenue This Year
- FAAS N/A
- NRSN N/A
- Revenue Next Year
- FAAS N/A
- NRSN N/A
- P/E Ratio
- FAAS N/A
- NRSN N/A
- Revenue Growth
- FAAS 38.16
- NRSN N/A
- 52 Week Low
- FAAS $0.16
- NRSN $0.51
- 52 Week High
- FAAS $3.50
- NRSN $2.60
- Technical
- Relative Strength Index (RSI)
- FAAS 46.66
- NRSN 51.33
- Support Level
- FAAS $0.43
- NRSN $1.92
- Resistance Level
- FAAS $0.78
- NRSN $2.07
- Average True Range (ATR)
- FAAS 0.08
- NRSN 0.13
- MACD
- FAAS -0.01
- NRSN -0.03
- Stochastic Oscillator
- FAAS 25.81
- NRSN 52.01
About FAAS DIGIASIA CORP
DigiAsia Corp operates as a holding company. The majority of DigiAsia's operations are currently conducted through its majority-owned entities, controlled entities and corporate joint venture. It is among the first embedded fintech as a service (EFaaS) companies in Indonesia serving business-to-business-to-consumer (B2B2C) customers, such as large corporations and state-owned enterprises, as well as business-to-business (B2B) customers, such as micro, small and medium-sized enterprise (MSME) merchants, across various segments. It aims to be a fintech-enabling platform in Southeast Asia by accelerating financial inclusion through its licenses and technology stack and combining the benefits of technological innovation with traditional financial services.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.